Blood Cancer Research
Providing High Quality and Internationally-Recognized Drug Development and Clinical Research for Blood Cancer
The SCRI blood cancer research program is a network of premier investigative sites comprised of thought leaders and first-class treatment programs focused on advancing blood cancer treatment. Other goals of the network include:
- Conducting clinical trials in blood cancer with efficiency and quality
- Delivering world-class hematopoietic cell transplantation
- Implementing investigator-initiated and industry-sponsored clinical trials
- Partnering with pharmaceutical and biotech companies to advance the treatment of blood cancer
Our integration of research, quality, training and technology ensures patient access to the highest standards of care.
Phase I-III Research Program:
- Leukemia, Myelodysplastic Syndrome and Myeloproliferative Disorders
- Lymphoma and Chronic Lymphocytic Leukemia
- Multiple Myeloma and Related Plasma Cell Malignancies
- Autologous and Allogeneic Blood and Marrow Transplant
- Cellular Therapy
Advantages of Collaboration:
- Infrastructure and support through expertise in clinical research
- Extensive clinical trial menu specializing in hematology trials
- Increased accruals to provide innovative therapies to patients
- Scientific collaboration with other investigators in the field
- Rapid access to novel therapies Increased breadth of research disease program
- Ability to expedite the process for drug approval from Phase I - III
Blood Cancer Research Network
- Sarah Cannon Transplant & Cellular Therapy Program at TriStar Centennial (Adult and Pediatric Programs) – Nashville, TN
- Colorado Blood Cancer Institute – Denver, CO
- Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital – Antonio, TX
- Sarah Cannon Transplant & Cellular Therapy Program at St. David’s South Austin Medical Center – Austin, TX
- Sarah Cannon Transplant & Cellular Therapy Program at Research Medical Center – Kansas City, MO